A detailed history of Jpmorgan Chase & CO transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 406,149 shares of KURA stock, worth $7.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
406,149
Previous 434,396 6.5%
Holding current value
$7.23 Million
Previous $9.27 Million 9.75%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$17.53 - $22.98 $495,169 - $649,116
-28,247 Reduced 6.5%
406,149 $8.36 Million
Q1 2024

May 10, 2024

SELL
$13.42 - $23.53 $517,958 - $908,163
-38,596 Reduced 8.16%
434,396 $9.27 Million
Q4 2023

Feb 12, 2024

SELL
$7.58 - $14.38 $67,287 - $127,651
-8,877 Reduced 1.84%
472,992 $6.8 Million
Q3 2023

Nov 14, 2023

SELL
$8.44 - $11.86 $173,712 - $244,102
-20,582 Reduced 4.1%
481,869 $4.39 Million
Q2 2023

Aug 11, 2023

SELL
$9.62 - $13.99 $103,617 - $150,686
-10,771 Reduced 2.1%
502,451 $5.32 Million
Q1 2023

May 18, 2023

BUY
$10.71 - $14.6 $862,701 - $1.18 Million
80,551 Added 18.62%
513,222 $6.28 Million
Q1 2023

May 11, 2023

SELL
$10.71 - $14.6 $870,101 - $1.19 Million
-81,242 Reduced 15.81%
432,671 $5.29 Million
Q4 2022

Feb 13, 2023

SELL
$11.23 - $16.9 $389,916 - $586,784
-34,721 Reduced 6.33%
513,913 $6.38 Million
Q3 2022

Nov 14, 2022

SELL
$12.01 - $19.45 $155,721 - $252,188
-12,966 Reduced 2.31%
548,634 $7.5 Million
Q2 2022

Aug 11, 2022

BUY
$10.71 - $18.33 $5.15 Million - $8.81 Million
480,848 Added 595.46%
561,600 $10.3 Million
Q1 2022

May 11, 2022

SELL
$11.78 - $16.98 $298,128 - $429,729
-25,308 Reduced 23.86%
80,752 $1.3 Million
Q4 2021

Feb 10, 2022

BUY
$12.22 - $19.57 $617,684 - $989,204
50,547 Added 91.05%
106,060 $1.49 Million
Q3 2021

Nov 12, 2021

BUY
$15.42 - $21.72 $856,010 - $1.21 Million
55,513 New
55,513 $1.04 Million

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $1.19B
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.